Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 29, 2015 4:04 PM ET


Company Overview of Tokai Pharmaceuticals, Inc.

Company Overview

Tokai Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. Its lead drug candidate, galeterone, is a multi-targeted, oral small molecule being developed for the treatment of patients with metastatic castration-resistant prostate cancer. The company’s ARDA drug discovery program is focused on the identification and evaluation of compounds that are designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation and are targeted to patients with androgen receptor signaling diseases, including prostate cancer. The company was founded in 2004 and is based in ...

255 State Street

6th Floor

Boston, MA 02109

United States

Founded in 2004

17 Employees



Key Executives for Tokai Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 40
Total Annual Compensation: $608.5K
Chief Financial Officer
Age: 34
Total Annual Compensation: $201.7K
Chief Medical Officer and Head of Research & Development
Age: 57
Total Annual Compensation: $408.8K
Compensation as of Fiscal Year 2014.

Tokai Pharmaceuticals, Inc. Key Developments

Tokai Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Tokai Pharmaceuticals, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $8,982,000 compared with $5,885,000 for the same period a year ago. Net loss was $8,957,000 or $0.40 per basic and diluted share compared with $5,851,000 or $11.68 per basic and diluted share for the same period a year ago. For the six months, the company reported loss from operations of $22,282,000 compared with $10,777,000 for the same period a year ago. Net loss was $22,217,000 or $0.99 per basic and diluted share compared with $10,698,000 or $21.48 per basic and diluted share for the same period a year ago.

Tokai Pharmaceuticals, Inc. Announces Initiation of Phase 3 ARMOR3-SV Trial of Galeterone in AR-V7 Positive Metastatic Castration-Resistant Prostate Cancer

Tokai Pharmaceuticals, Inc. announced the initiation of ARMOR3-SV, the company's pivotal Phase 3 clinical trial of galeterone in men with metastatic castration-resistant prostate cancer (mCRPC) whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor (AR) that has been associated with non-responsiveness to commonly-used oral therapies for mCRPC. The company also announced that the components of the AR-V7 clinical trial assay have been finalized by its collaborator, Qiagen, and that global deployment of the assay is now underway. ARMOR3-SV will compare galeterone to Xtandi® (enzalutamide) in 148 mCRPC treatment-naïve patients whose prostate tumors express the AR-V7 splice variant. These truncated ARs are missing the C-terminal end of the AR that contains the ligand-binding domain, which is known as C-terminal loss. AR-V7 is the most common form of C-terminal loss. The pivotal trial will employ a precision medicine approach for selection of patients with the AR-V7 splice variant by using an AR-V7 clinical trial assay successfully optimized for global use by Qiagen. The primary endpoint of ARMOR3-SV is radiographic progression-free survival assessed by blinded independent central review. The design of ARMOR3-SV is aligned with feedback obtained from the U.S. Food and Drug Administration and the European Medicines Agency. ARMOR3-SV has been initiated at more than 15 sites in the United States, with site initiations in Canada and the United Kingdom anticipated later in June. Additional study centers throughout North America, Western Europe and Australia are expected to join the study in the coming months. In addition, with recent finalization of the components of the AR-V7 clinical trial assay, technology transfer activities and training of the global central laboratories are underway, and screening of eligible patients for the splice variant is expected to begin in July. The company expects topline data from ARMOR3-SV to be available by the end of 2016.

Tokai Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 12:30 PM

Tokai Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 12:30 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: Lee H. Kalowski, Chief Financial Officer.

Similar Private Companies By Industry

Company Name Region
PxRadia, Inc. United States
SABiosciences Corporation United States
HSRx Group, LLC United States
Kim Laboratories, Inc. United States
BioConsortia, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tokai Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at